Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd (symbol: CGEN) is a cutting-edge drug discovery company specializing in developing therapeutic proteins and monoclonal antibodies to meet critical needs in immunology and oncology. By leveraging a sophisticated infrastructure of proprietary scientific insights, predictive platforms, algorithms, and machine learning systems, Compugen excels in in silico (computer-based) prediction and selection of promising product candidates for its pipeline program.
Compugen's business model is robust and diversified, encompassing partnerships and collaborations for the further development and commercialization of its product candidates. These collaborations typically offer milestone payments and royalties on product sales, providing Compugen with multiple revenue streams. The company's U.S. subsidiary, based in South San Francisco, focuses on developing monoclonal antibodies.
At the core of Compugen's operations is its clinical-stage therapeutic discovery and development efforts, primarily in cancer immunotherapy. Its comprehensive immuno-oncology pipeline includes four clinical-stage programs, each targeting immune checkpoints discovered through computational methods. Notable programs include COM701, COM902, and bapotulimab. These programs are designed to tackle various mechanisms of immune resistance, with a particular focus on myeloid targets.
Recent achievements highlight Compugen's forward momentum. The company announced it would release its fourth quarter and full-year 2023 financial results on March 5, 2024. Compugen's President and CEO, Anat Cohen-Dayag, emphasized the company's strong financial footing, collaboration successes, and the anticipated catalytic milestones in 2024.
Key partnerships enhance Compugen’s clinical progress. For instance, the company has a license agreement with Gilead Sciences for COM503, a first-in-class antibody program against IL-18 binding protein. This agreement includes a $60 million upfront payment and a $30 million milestone payment upon IND clearance.
Another significant partnership is with AstraZeneca, which is advancing a PD-1/TIGIT bispecific antibody derived from Compugen's COM902 into Phase 3 development. This program, rilvegostomig, targets biliary tract cancer and nonsquamous non-small cell lung cancer. These collaborations underscore the extensive potential and validation of Compugen's computational discovery platform.
Compugen's financial health is robust, with a reported cash balance of $101.3 million as of March 31, 2024, ensuring operational funding into 2027. The company has demonstrated prudent financial management, achieving net revenues and reducing operational losses over time.
Headquartered in Israel, with additional offices in San Francisco, Compugen is listed on both Nasdaq and the Tel Aviv Stock Exchange, making it a prominent player in the biotech sector. For investors and stakeholders, Compugen represents a beacon of innovation and potential in cancer immunotherapy.
Compugen Ltd. (Nasdaq: CGEN) announces it will release its second quarter 2021 financial results on July 28, 2021, before U.S. markets open. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. The call can be accessed via telephone or through a live webcast on the company's website. Compugen is focused on cancer immunotherapy with key products like COM701 and COM902 undergoing clinical studies.
Compugen Ltd. (NASDAQ: CGEN) has announced the dosing of the first patient in a combination expansion cohort of its Phase 1 clinical trial for COM701, an anti-PVRIG antibody, in conjunction with Opdivo® (nivolumab). This cohort targets ovarian, breast, endometrial, and colorectal cancers, following encouraging initial results showing complete responses and durable anti-tumor activity. The trial aims to evaluate the safety and efficacy of the therapy in advanced solid tumors, reinforcing Compugen's position in cancer immunotherapy.
Compugen Ltd. (CGEN) presented new research on PVRIG, emphasizing its role as a distinct immune checkpoint that may enhance T-cell expansion. Findings suggest that PVRIG clusters with early memory T cell markers, indicating its potential when used with TIGIT and PD-1 inhibitors for tumors unresponsive to current therapies. The study highlights PVRIG's expression in T cells and its potential to trigger immune responses. The presentation was made at the SITC 2021 seminar.
Compugen Ltd. (Nasdaq: CGEN) presented updated data from its Phase 1 study of COM701, a first-in-class anti-PVRIG antibody, at ASCO 2021. The combination of COM701 with Opdivo® demonstrated a 66.7% disease control rate in 15 evaluable patients, with a notable complete response in a patient with anal squamous cell carcinoma lasting 22 months. The monotherapy showed a 47.2% disease control rate across 36 patients, with preliminary biomarker data indicating enhanced immune response. These findings highlight the potential for COM701 in difficult-to-treat cancers, including ongoing evaluation in immunotherapy-resistant populations.
Compugen Ltd. (Nasdaq: CGEN) announced participation in a virtual event to discuss data from its Phase 1 clinical trial of COM701, an innovative antibody targeting PVRIG. The findings will be presented on June 7, 2021, at the ASCO 2021 Annual Meeting. A fireside chat hosted by Truist Securities analyst Asthika Goonewardene is scheduled for June 8, 2021, featuring key executives from Compugen. The company is focused on developing cancer immunotherapy treatments, including the ongoing studies of COM701 and COM902.
Compugen Ltd. (CGEN) reported Q1 2021 financial results with a net loss of $9.9 million or $0.12 per share, an increase from a $7.1 million loss in Q1 2020. R&D expenses rose to $7.3 million, up from $4.7 million, driven by drug manufacturing and clinical activities. The company has $119.4 million in cash reserves. Upcoming milestones include data readouts for COM701 in various studies and collaboration with Bristol Myers Squibb for a Phase 1b study. Compugen aims to lead in the DNAM axis space with promising clinical data for PVRIG and TIGIT assets.
Compugen Ltd. (NASDAQ: CGEN) announced that Eran Ophir, Ph.D., Vice President of Research and Drug Discovery, will participate in the Society for Immunotherapy of Cancer's online seminar on June 29, 2021. The seminar focuses on 'The TIGIT Pathway' and is part of a series addressing key questions in cancer immunotherapy. Co-chairs include industry experts, and an interactive Q&A session will follow. Compugen, based in Israel, is developing innovative cancer therapies, including its lead anti-PVRIG antibody, COM701, currently in Phase 1 trials.
Compugen Ltd. (CGEN) announced an expansion of its research collaboration with Johns Hopkins University on a novel myeloid target discovered through its predictive computational platform. Initial preclinical studies indicate significant tumor growth inhibition upon genetic deletion of this target, potentially serving as a myeloid immunomodulator. The collaboration aims to further investigate the biological function of this target, enhancing Compugen's immuno-oncology pipeline. The CEO emphasizes the importance of early-stage programs for the company's growth and development in cancer therapies.
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, will release its first quarter 2021 financial results on May 13, 2021, before U.S. markets open. A conference call will be held at 8:30 AM ET to discuss the results and provide an update. Investors can join via telephone or through a live webcast on Compugen's website. The company is advancing its lead candidate, COM701, an anti-PVRIG antibody for solid tumors, which is currently in a Phase 1 clinical study, alongside COM902, targeting TIGIT.
Compugen Ltd. (CGEN) announced an oral presentation at the ASCO 2021 Annual Meeting, scheduled for June 7, 2021. The presentation will provide updates on the ongoing Phase 1 trial of COM701, a therapeutic antibody targeting PVRIG for advanced solid tumors. Noteworthy details include the title of the oral presentation and its focus on the safety, tolerability, and preliminary antitumor activity of COM701, evaluated with or without nivolumab. The abstract will be accessible on May 19, 2021, on ASCO.org.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
What is Compugen Ltd's primary business focus?
What makes Compugen unique in the biotech industry?
Who are Compugen's key partners?
What are some of Compugen's notable products?
What recent financial milestones has Compugen achieved?
Where is Compugen Ltd headquartered?
On which stock exchanges are Compugen's shares listed?
What are some of Compugen's recent achievements?
What is the significance of Compugen’s computational discovery platform?
What is Compugen's approach to advancing its pipeline?
